Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited

Navigating SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Exelixis, Inc. and Opthea Limited from 2014 to 2023.

Exelixis, Inc.: A Steady Climb

Exelixis, Inc. has seen a remarkable increase in SG&A expenses, growing nearly tenfold over the decade. Starting at approximately $51 million in 2014, the expenses surged to over $540 million by 2023, reflecting the company's expansion and increased operational activities.

Opthea Limited: A Gradual Rise

Opthea Limited, while smaller in scale, also experienced a significant rise in SG&A expenses, from around $2.7 million in 2014 to $41.9 million in 2023. This growth underscores Opthea's strategic investments in its administrative and sales functions.

Both companies demonstrate the critical role of SG&A expenses in supporting their strategic objectives, albeit with different scales and growth trajectories.